| Systematic (IUPAC) name | |
|---|---|
| 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one | |
| Clinical data | |
| Trade names | Vidaza |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a607068 |
| Pregnancy cat. | D (US), X (Aus) |
| Legal status | ? |
| Routes | SubQ, IV |
| Pharmacokinetic data | |
| Metabolism | possible hepatic metabolism, mostly urinary excretion |
| Half-life | 4 hr. [1] |
| Identifiers | |
| CAS number | 320-67-2 |
| ATC code | L01BC07 |
| PubChem | CID 9444 |
| DrugBank | DB00928 |
| ChemSpider | 9072 |
| UNII | M801H13NRU |
| KEGG | D03021 |
| ChEBI | CHEBI:2038 |
| ChEMBL | CHEMBL1489 |
| Synonyms | 5-azacytidine |
| Chemical data | |
| Formula | C8H12N4O5 |
| Mol. mass | 244.205 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| |
|
Azacitidine (INN) or 5-azacytidine, sold under the trade name Vidaza, is a chemical analogue of cytidine, a nucleoside present in DNA and RNA. Azacitidine and its deoxy derivative, decitabine (also known as 5-aza-2′deoxycytidine), are used in the treatment of myelodysplastic syndrome. Both drugs were first synthesized in Czechoslovakia as potential chemotherapeutic agents for cancer.[2]
Azacitidine has also been used as an experimental treatment in clinical trials involving cases of acute myeloid leukemia, where the patient has suffered more than one relapse- in these cases, standard chemotherapy, hematopoietic stem cell transplantation, and other mainline treatments have failed.
|
Contents
|
Azacitidine is mainly used in the treatment of myelodysplastic syndrome (MDS), for which it received approval by the U.S. Food and Drug Administration on May 19, 2004; it is marketed as Vidaza.[3] In a randomized controlled trial comparing azacitidine to supportive treatment of MDS, around 16% of people receiving the drug had a complete or partial response—blood cell counts and bone marrow morphology returning to normal—and 2/3 patients who required blood transfusions before the study no longer needed them after receiving azacitidine.[4]
It can also be used in vitro to remove methyl groups from DNA. This may weaken the effects of gene silencing mechanisms that occurred prior to the methylation. Methylation events are therefore believed to secure the DNA in a silenced state. Demethylation may reduce the stability of silencing signals and thus confer relative gene activation.[5]
Azacitidine (5-azacytidine) is a chemical analogue of the cytosine nucleoside used in DNA and RNA. Azacitidine is thought to induce antineoplastic activity via two mechanisms; inhibition of DNA methyltransferase at low doses, causing hypomethylation of DNA, and direct cytotoxicity in abnormal hematopoietic cells in the bone marrow through its incorporation into DNA and RNA at high doses, resulting in cell death. As azacitidine is a ribonucleoside, it incoporates into RNA to a larger extent than into DNA. The incorporation into RNA leads to the dissembly of polyribosomes, defective methylation and acceptor function of transfer RNA, and inhibition of the production of protein. Its incorporation into DNA leads to a covalent binding with DNA methyltransferases, which prevents DNA synthesis and subsequent cytotoxicity.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)